SGMO – Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc.SGMO
$0.5616Name : Sangamo Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $137,817,776.00
EPSttm : -0.36
Sangamo Therapeutics, Inc.
$0.5616
4.56%$0.0245Float Short %
9.83
Margin Of Safety %
Put/Call OI Ratio
0.23
EPS Next Q Diff
0.02
EPS Last/This Y
EPS This/Next Y
0.12
Price
0.56
Target Price
4.1
Analyst Recom
1.83
Performance Q
-24.23
Relative Volume
0.77
Beta
1.19
Ticker: SGMO
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-04 | SGMO | 0.5269 | 0.30 | 0.00 | 75607 |
| 2025-07-07 | SGMO | 0.5135 | 0.30 | 0.09 | 76136 |
| 2025-07-08 | SGMO | 0.5111 | 0.30 | 0.29 | 76919 |
| 2025-07-09 | SGMO | 0.5309 | 0.30 | 0.00 | 77156 |
| 2025-07-10 | SGMO | 0.5 | 0.30 | 0.14 | 77979 |
| 2025-07-11 | SGMO | 0.4918 | 0.29 | 0.03 | 78779 |
| 2025-07-14 | SGMO | 0.5017 | 0.29 | 0.72 | 79197 |
| 2025-07-15 | SGMO | 0.4802 | 0.29 | 0.00 | 79488 |
| 2025-07-16 | SGMO | 0.4801 | 0.29 | 0.02 | 81000 |
| 2025-07-17 | SGMO | 0.4876 | 0.29 | 0.00 | 81107 |
| 2025-07-18 | SGMO | 0.5019 | 0.28 | 0.00 | 82164 |
| 2025-07-21 | SGMO | 0.4945 | 0.29 | 0.06 | 77616 |
| 2025-07-22 | SGMO | 0.48 | 0.28 | 0.01 | 78732 |
| 2025-07-23 | SGMO | 0.5543 | 0.26 | 0.04 | 78284 |
| 2025-07-24 | SGMO | 0.5979 | 0.25 | 0.06 | 81785 |
| 2025-07-25 | SGMO | 0.586 | 0.24 | 0.06 | 88741 |
| 2025-07-28 | SGMO | 0.6024 | 0.23 | 0.11 | 89323 |
| 2025-07-29 | SGMO | 0.57 | 0.24 | 0.00 | 91899 |
| 2025-07-30 | SGMO | 0.5445 | 0.23 | 0.33 | 94629 |
| 2025-07-31 | SGMO | 0.5349 | 0.23 | 0.02 | 97163 |
| 2025-08-01 | SGMO | 0.5604 | 0.23 | 0.07 | 97986 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-04 | SGMO | 0.53 | 27.1 | - | -0.49 |
| 2025-07-07 | SGMO | 0.51 | 27.1 | - | -0.49 |
| 2025-07-08 | SGMO | 0.51 | 27.1 | - | -0.49 |
| 2025-07-09 | SGMO | 0.53 | 27.1 | - | -0.49 |
| 2025-07-10 | SGMO | 0.50 | 27.1 | - | -0.49 |
| 2025-07-11 | SGMO | 0.49 | 27.1 | - | -0.49 |
| 2025-07-14 | SGMO | 0.50 | 27.1 | - | -0.49 |
| 2025-07-15 | SGMO | 0.48 | 27.1 | - | -0.49 |
| 2025-07-16 | SGMO | 0.48 | 27.1 | - | -0.49 |
| 2025-07-17 | SGMO | 0.48 | 27.1 | - | -0.49 |
| 2025-07-18 | SGMO | 0.50 | 27.1 | - | -0.49 |
| 2025-07-21 | SGMO | 0.49 | 27.1 | - | -0.49 |
| 2025-07-22 | SGMO | 0.48 | 27.1 | - | -0.49 |
| 2025-07-23 | SGMO | 0.55 | 27.1 | - | -0.49 |
| 2025-07-24 | SGMO | 0.60 | 27.1 | - | -0.49 |
| 2025-07-25 | SGMO | 0.59 | 27.1 | - | -0.49 |
| 2025-07-28 | SGMO | 0.60 | 27.1 | - | -0.49 |
| 2025-07-29 | SGMO | 0.57 | 27.1 | - | -0.49 |
| 2025-07-30 | SGMO | 0.55 | 27.1 | - | -0.49 |
| 2025-07-31 | SGMO | 0.54 | 27.1 | - | -0.49 |
| 2025-08-01 | SGMO | 0.56 | 27.1 | - | -0.49 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-04 | SGMO | 0.00 | -14.57 | 10.80 |
| 2025-07-07 | SGMO | 0.00 | -14.62 | 10.80 |
| 2025-07-08 | SGMO | 0.00 | -14.62 | 10.80 |
| 2025-07-09 | SGMO | 0.00 | -14.62 | 10.80 |
| 2025-07-10 | SGMO | 0.00 | -14.62 | 10.80 |
| 2025-07-11 | SGMO | 0.00 | -14.62 | 10.17 |
| 2025-07-14 | SGMO | 0.00 | -14.62 | 10.17 |
| 2025-07-15 | SGMO | 0.00 | -14.62 | 10.17 |
| 2025-07-16 | SGMO | 0.00 | -14.62 | 10.17 |
| 2025-07-17 | SGMO | 0.00 | -14.62 | 10.17 |
| 2025-07-18 | SGMO | 0.00 | -14.62 | 10.17 |
| 2025-07-21 | SGMO | 0.00 | -15.43 | 10.17 |
| 2025-07-22 | SGMO | 0.00 | -15.43 | 10.17 |
| 2025-07-23 | SGMO | 0.00 | -15.43 | 10.17 |
| 2025-07-24 | SGMO | 0.00 | -15.43 | 10.17 |
| 2025-07-25 | SGMO | 0.00 | -15.43 | 9.83 |
| 2025-07-28 | SGMO | 0.00 | -14.57 | 9.83 |
| 2025-07-29 | SGMO | 0.00 | -14.57 | 9.83 |
| 2025-07-30 | SGMO | 0.00 | -14.57 | 9.83 |
| 2025-07-31 | SGMO | 0.00 | -14.57 | 9.83 |
| 2025-08-01 | SGMO | 0.00 | -14.57 | 9.83 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.14
Avg. EPS Est. Current Quarter
-0.1
Avg. EPS Est. Next Quarter
-0.13
Insider Transactions
Institutional Transactions
-14.57
Beta
1.19
Average Sales Estimate Current Quarter
29
Average Sales Estimate Next Quarter
6
Fair Value
Quality Score
4
Growth Score
29
Sentiment Score
24
Actual DrawDown %
97.1
Max Drawdown 5-Year %
-98.4
Target Price
4.1
P/E
Forward P/E
PEG
P/S
2.16
P/B
25.8
P/Free Cash Flow
EPS
-0.38
Average EPS Est. Cur. Y
-0.49
EPS Next Y. (Est.)
-0.38
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-126.63
Relative Volume
0.77
Return on Equity vs Sector %
-1643.2
Return on Equity vs Industry %
-1624.5
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.03
EBIT Estimation
Sangamo Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 183
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
stock quote shares SGMO – Sangamo Therapeutics, Inc. Stock Price stock today
news today SGMO – Sangamo Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SGMO – Sangamo Therapeutics, Inc. yahoo finance google finance
stock history SGMO – Sangamo Therapeutics, Inc. invest stock market
stock prices SGMO premarket after hours
ticker SGMO fair value insiders trading